Adjuvant therapy for colon cancer

Ca-A Cancer Journal for Clinicians

Volumn 47, Issue 4, 1997, Pages 243-256

  Macdonald, John S ^a  

^a TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; EDRECOLOMAB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; LEVAMISOLE; SEMUSTINE; VINCRISTINE;

ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIARRHEA; DRUG COST; DYSGEUSIA; HUMAN; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; META ANALYSIS; MOLECULAR GENETICS; NEUROTOXICITY; NEUTROPENIA; PORTAL VEIN; PRIORITY JOURNAL; PROGNOSIS; STOMATITIS; SURVIVAL TIME;

EID: 0030826303     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.47.4.243     Document Type: Article

References (54)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics. 1997. CA Cancer J Clin 1997;47:5-27.
2. Kokal W, Sheibani K, Terz J. et al: Tumor DNA content in the prognosis of colorectal carcinoma. JAMA 1986;225:3123-3127.
3. Bauer KD, Bagwell CB, Giaretti W, et al: Consensus review of the clinical utility of DNA flow cytomentry in colorectal cancer. Cytometry 1993;14:486-491.
4. Tomoda H, Kakeji Y, Furusawa M: Prognostic significance of flow cytometric analysis of DNA content in colorectal cancer: A prospective study. J Surg Oncol 1993;53:144-148.
5. O'Connell MJ, Schaid DJ, Ganju V, et al: Current status of adjuvant chemotherapy for colorectal cancer: Can molecular marker play a role in predicting prognosis? Cancer 1992;70 (Suppl 6): 1732-1739.
6. Zeng ZS, Sarkis AS, Zhang ZF, et al: p53 nuclear overexpression: An independent predictor of survival in lymph node-positive colorectal cancer patients. J Clin Oncol 1994;12:2043-2050.
7. Jen J, Kim H, Piantadosi S, et al: Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994;331:213-221.
8. Cohen AM, Shank B, Friedman MA: Colorectal cancer, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, ed 3. Philadelphia. JB Lippincott. 1989. pp 895-964.
9. Potter JD, Slattery ML, Bostick RM, et al: Colon cancer: A review of the epidemiology. Epidemiol Rev 1993;15:499-545.
10. Buyse M, Zeleniuch-Jacquotte A, Chalmer TC: Adjuvant therapy of colorectal cancer: Why we still don't know. JAMA 1988;259:3571-3578.
11. Higgins GA Jr, Amadeo JH, McElhinney J, et al: Efficacy of prolonged intermittent therapy will combined 5-fliorouracil and methyl-CCNU following resection for carcinoma of the large bowel: A Veterans Administration Surgical Oncology Group report. Cancer 1984;53:1-8.
12. Gastrointestinal Tumor Study Group: Adjuvant therapy of colon cancer: Result of a prospectively randomized trial. N Engl J Med 1984;310:737-743.
13. Panettiere FJ, Goodman PJ, Costanzi JJ, et al: Adjuvant therapy in bowel adenocarcinoma: Long-term results of a Southwest Oncology Group study. J Clin Oncol 1988;6:947-954.
14. Wolmark N, Fisher B, Rockette H, et al: Postoperative adjuvant chemotherapy or BCG for colon cancer. Results from NSABP Protocol C-01. J Natl Cancer Inst 1988;80:30-36.
15. Boice JD Jr, Greene MN, Killen JY, et al: Leukemia and prleukemia after adjuvant treatmentment of gastrointestinal cancer with semustine methyl-CCNUJ. N Engl J Med 1983;309:1079-1084.
16. Laurie JA, Moertel CG, Fleming TR, et al: Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouacil: The North Central Cancer Treatment Group and Mayo Clinic. J Clin Oncol 1989;7:1447-1456.
17. Moertel CG, Fleming TR, Macdonald JS. et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;312:352-358.
18. Moertel C, Fleming T, Macdonald J, et al: The intergroup study of 5-fluorouracil (5- FU) plus levamisole (LEV) and levamisole alone as adjuvant therapy for stage C colon cancer. A final report. Proc Am Soc Clin Oncol 1992;11:161. Abstract.
19. Moertel CG, Fleming TR, Macdonald JS, et al: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 1995; 122:321-326.
20. Moertel CG, Fleming TR, Macdonal JS. et al: al: Intergroup study of fluorouracil plus levamsole as adjuvant therapy for stage II Duke B2 colon cancer. J Clin Oncol 1995;13:2936-2943.
21. Shulman K, Schilsky RL: Adjuvant therapy of colon cancer. Semin Oncol 1995;22:600-610.
22. NIH Consensus Conference: Adjuvant thera py for patients with colon and rectal cancer. JAMA 1990;264:1444-1450.
23. Leichman CG, Fleminge TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. J Clin Oncol 1995;13:13:1303-1311.
24. Taylor I, Machin D, Mullee M, et al: A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg 1985;72:359-363.
25. Gray BN, Dezwart J, Fisher R, et al: The Australia and New Zealand trial of adjuvant chemotherapy in colon cancer, in Salmon SEW (ed): Adjuvant Therapy of Cancer V. Orlando. Grune & Stratton. 1987. pp 537-554.
26. Wereldsma JCJ, Bruggink ED, Meijer WS, et al: Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control: Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I). Cancer 1990;65:425-432.
27. Swiss Group for Clinical Cancer Research (SAKK): Long-term results of single course of adjuvant important chemotherapy for colorectal cancer. Lancet 1995;345:349-353.
28. Beart RW Jr, Moertel CG, Wieand HS, et al: Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion: A study of the Mayo clinic and the North Central Cancer Treatment Group. Arch Surg 1990;125:897-901.
29. Wolmark N, Rockette H, Wickerham DL, et al: Adjuvant therapy of Dukes' A. B and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: Preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol 1990;8:1466-1475.
30. Wolmark N, Rockette H, Petrelli N, et al: Long-term results of the efficacy of perioperative portal vein infusion of 5-FU for treatment of colon cancer: NSABP C-02. Proc Am Soc Clin Oncol 1994;13:194. Abstract.
31. Fielding LP, Hittinger R, Grace RH, et al: Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. Lancet 1992;340:502-506.
32. Riethmuller G, Schneider-Gadicke E, Schlimok G, et al: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' colorectal carcinoma: German Cancer Aid 17-1A Study Group, Lancet 1994;343:1177-1183.
33. Foon KA, Bhattacharya-Chatterjee, Chakraborty WJ, et al: Murine anti-idiotype monoclonal antibody induces specific humoral responses to carcinoembryonic antigen (CEA) in Colorectal cancer patients. Proc Am Soc Clin Oncol 1994;13:294. Abstract.
34. Haller DG, Catalano PJ, Macdonald JS. et al: Fluorouracil (FU). leueovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer Preliminary results of INT-0089. Proc Am Soc Clin Oncol 1996;15:211.
35. Wolmark N, Rockette H, Mamounas EP, et al: The relative efficacy of 5-FU + leucovorin (FU-LV), 5-FU + levamisole (FU-LEV) leucovorin + levamisole (FU-LV-LEV) in patients with Dunkes' B and C carcinoma of the colon: First report of NSABP C-04. Proc Am Soc Clin Oncol 1996;15:205. Abstract.
36. O'Connell MJ, Laurie JA, Shepherd L, et al: A prospectice evaluation of chemotherapy duration and regiment as surgical adjuvant treatment for high-risk colon cancer: A collaborative trial of the North Central Cancer Treatment Group and The National Cancer Institiute of Canada Clinical Trial Group. Proc Am Soc Clin Oncol 1996;15:209. Abstract.
37. Advanced Colorectal Cancer Met-Analysis Project: Modulation of fluorouracil by leucocorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
38. O'Connell MJ, Mailliard JA, Kahn MJ, et al: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997;15:246-250.
39. Wolmark N, Rockette H, Fisher B, et al: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Brest and Bowel Project C-03. J Clin Oncol 1993;11:1879-1887.
40. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT): Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345:939-944.
41. Francini G, Petrioli R, Lorenzini L, et al: Folinic acid and 5-fluorouracil as adjuvant chemotherapy in cancer. Gastroenterology 1994;106:899-906.
42. Piedbois P, Buyse M, Gray R, et al: Portal vein infusion is an effective adjuvant treatment for patients with colorectal cancer. Proc Am Soc Clin Oncol 1995;14:192. Abstract.
43. Crowley JJ: Perioperative portal vein chemotherapy, in ASCO Educational Book 1994. Chicago, American Society of Clinical Oncology, 1994, p 171.
44. Davies N, Kynaston H, Yated J, et al: Reticuloendothelial stimulation: Levamisole compared. Dis Colon Rectum 36;1993:1054-1058.
45. Taylor DD, Gercel-Taylor C, Fowler WC, et al: Enhancement of antitumor effects of combined chemoimmunotherapy. J Immunother 1993;13:91-97.
46. Holcombe RF, Stewart RM, Betzing K, et al: Alteration of lymphocyte phenotype in patients receiving adjuvant 5FU-levamisole. Proc Am Soc Clin Oncol 1993;12:295. Abstract.
47. Holcombe RF, Stewart RM, Betzing K, et al: Clinical outcome in patients with Dukes' stage C colon cancer correlates with changes in natural killer (NK) cells and CD8+ T-cells during adjuvant therapy with 5-FU and levamisole. Proc Am Soc Clin Onclol 1994;13:228. Abstract.
48. Schiller JH, Lindstrom M, Witt PL, et al: Immunological effects of levamisole in vitro. J Immunother 1991;10:297-306.
49. Clinical Immunology Society: New progress in immunotherapy for colorectal cancer patients. Clin Immunol Spectrum 1994;6:1.
50. Hodi FS, Catalano P, Macdonald JS, et al: Age as a factor influencing the toxicity of adjuvant chemotherapy for colrectal cancer. Pending submission, 1996.
51. Haller DG, Catalano P, Macdonald JS, et al: Gender as a factor influencing the toxicity of adjuvant chemotherapy for colorectal cancer. Second International Conderence on Biology, Prevention, and Treatment of Gastrointestinal Malignancies, Koln, Germany, January 1995. Abstract.
52. Mamounas EP, Rockette H, Jones J, et al: Comparative efficacy of adjuvant chemotherapy in patients with Dikes' B vs C colon cancer: Results from four NSABP adjuvant studies (EO1, EO2, EO3, EO4). Proc Am Soc Clin Oncol 1996;15:205. Abstract.
53. Brown ML, Nayfield SG, Shibley LM: Adjuvant therapy for stage III colon cancer: Economics returns to research and cost-effectiveness of treatment. J Natl Cancer Inst 1994;86:424-430.
54. O'Connell MJ: Surgical adjuvant of therapy of colorectal cancer, in ASCO Educational Book 1994. Chicago, American Society of Clinical Oncology, 1994.